Gene · 51185
Papers2,935
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
581 to 600 of 2,935
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Molecular and immunological mechanisms of clonal evolution in multiple myeloma. | Front Immunol | 2023 | 37744361 | PubTator, text mining | PubMed |
| Differential Diagnosis and Therapeutic Advances in Multiple Myeloma: A Review Article. | Blood Lymphat Cancer | 2023 | 37731771 | PubTator, text mining | PubMed |
| Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance. | Nat Commun | 2023 | 37730678 | PubTator, text mining | PubMed |
| Phase separation and pathologic transitions of RNP condensates in neurons: implications for amyotrophic lateral sclerosis, frontotemporal dementia and other neurodegenerative disorders. | Front Mol Neurosci | 2023 | 37720552 | PubTator, text mining | PubMed |
| Precision Oncology Comes of Age: Designing Best-in-Class Small Molecules by Integrating Two Decades of Advances in Chemistry, Target Biology, and Data Science. | Cancer Discov | 2023 | 37712571 | PubTator, text mining | PubMed |
| Model based assessment of food and acid reducing agent effects on oral absorption of mezigdomide (CC-92480), a novel cereblon E3 ligase modulator. | CPT Pharmacometrics Syst Pharmacol | 2023 | 37705327 | PubTator, text mining | PubMed |
| Mezigdomide Data Show CELMoD Potential. | Cancer Discov | 2023 | 37694945 | PubTator, text mining | PubMed |
| Harnessing the Immune System: An Effective Way to Manage Diffuse Large B-Cell Lymphoma. | J Hematol | 2023 | 37692863 | PubTator, text mining | PubMed |
| The Influence of KE and EW Dipeptides in the Composition of the Thymalin Drug on Gene Expression and Protein Synthesis Involved in the Pathogenesis of COVID-19. | Int J Mol Sci | 2023 | 37686182 | PubTator, text mining | PubMed |
| Recent advances in targeting the "undruggable" proteins: from drug discovery to clinical trials. | Signal Transduct Target Ther | 2023 | 37669923 | PubTator, text mining | PubMed |
| RAIDS atlas of significant genetic and protein biomarkers in cervical cancer. | J Gynecol Oncol | 2023 | 37668079 | PubTator, text mining | PubMed |
| Targeting reversible post-translational modifications with PROTACs: a focus on enzymes modifying protein lysine and arginine residues. | J Enzyme Inhib Med Chem | 2023 | 37667522 | PubTator, text mining | PubMed |
| Cereblon: A promising E3 ligase for broad-spectrum anticancer PROTAC drug development? | Pharmacol Res | 2023 | 37657656 | PubTator, text mining | PubMed |
| Rational design of small-molecule responsive protein switches. | Protein Sci | 2023 | 37656809 | PubTator, text mining | PubMed |
| PROTAC chemical probes for histone deacetylase enzymes. | RSC Chem Biol | 2023 | 37654508 | PubTator, text mining | PubMed |
| Activity-based profiling of cullin-RING E3 networks by conformation-specific probes. | Nat Chem Biol | 2023 | 37653169 | PubTator, text mining | PubMed |
| Emerging synthetic drugs for the treatment of diffuse large B-cell lymphoma. | Expert Opin Emerg Drugs | 2023 | 37649373 | PubTator, text mining | PubMed |
| Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma. | N Engl J Med | 2023 | 37646702 | PubTator, text mining | PubMed |
| PROTAC-mediated Degradation of HIV-1 Nef Efficiently Restores Cell-surface CD4 and MHC-I Expression and Blocks HIV-1 Replication. | bioRxiv | 2023 | 37645900 | PubTator, text mining | PubMed |
| How many kinases are druggable? A review of our current understanding. | Biochem J | 2023 | 37642371 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/51185/papers?page=30